John P. Kennedy to lead Pfizer CR
29.03.2016Company: Pfizer, spol. s r.o.
Effective from 1 March 2016, John P. Kennedy (1974) became a new County Manager of Pfizer in the Czech Republic. He comes to head the Czech branch from the United States. In his position he will also be responsible for the management of the Global Innovative Pharma (GIP) business unit.
John P. Kennedy has replaced John Raney who returned to the US after four successful years as the Country Manager of the Czech branch to assume the role of the Global Marketing Director responsible for smoking cessation.
John P. Kennedy has held various positions at Pfizer in the US since 1999. During his 17 years at Pfizer he served in many different roles. John started in Regulatory Affairs, where he became the Global Regulatory Strategy Lead for cardiovascular and endocrine programs. He has worked in various marketing positions since 2003. Between 2010 and 2013 he headed the marketing division of the US Primary Care unit in the area of the central nervous system, Women’s Health, allergies and respiratory diseases, urology, etc. He spent the past three years working as the Sales Director of the GIP unit for the north-west of the US where he was, besides other things, in charge of a sales team of 200 people active across 10 US states.
Kennedy studied biology and the German language at the Fairfield University in the US. He was also awarded an MBA degree in Finance, Marketing and International Trade at the NYU Stern School of Business in New York.
He is married and has two daughters. His hobbies include sports; he completed his first full distance Ironman Triathlon in 2015.
___________________________________________________________________________
About Pfizer Czech Republic
Pfizer Inc. is one of the world’s premier biopharmaceutical companies active in research and development of its own pharmaceuticals. It has a seat in New York, US, since it launched its activities in 1849. The Pfizer branch in the Czech Republic was established in 1993. It focuses on research, development and sale of human medicines, both biologicals and vaccines. It performs clinical trials of new medicines, also in the Czech Republic. In 2014 global Pfizer investments in research and development of new pharmaceuticals amounted to more than CZK 200 billion (USD 8.3 billion). Pfizer employs more than 97,000 people worldwide. The Czech branch has more than 200 employees.
To learn more, please visit: www.pfizer.cz
